Brian L. Wells
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Blood Coagulation and Thrombosis Mechanisms, Atrial Fibrillation Management and Outcomes, Chemical Synthesis and Analysis, Coagulation, Bradykinin, Polyphosphates, and Angioedema, Peptidase Inhibition and Analysis
Most-Cited Works
- → Discovery of 1-(2-Aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2‘-(aminosulfonyl)[1,1‘-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor(2003)75 cited
- → 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa(2006)63 cited
- → Structure–activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors(2007)36 cited
- → Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties(2006)29 cited
- → (N-acyl-N-alkyl)glycyl borolysine analogs: A new class of potent thrombin inhibitors(1996)15 cited
- → The de novo design and synthesis of cyclic urea inhibitors of factor Xa: optimization of the S4 ligand(2000)14 cited
- → Biochemical and Crystallographic Characterization of Homologous Non-peptidic Thrombin Inhibitors Having Alternate Binding Modes(1998)1 cited
- → ChemInform Abstract: (N‐Acyl‐N‐alkyl)glycyl Borolysine Analogues: A New Class of Potent Thrombin Inhibitors.(1997)